Crossmark

Intranasal Liposomal Trimetazidine Nanocarriers Modulate Neuroinflammation and Neurotransmission via the HMGB1/TLR4/NF-κB Pathway in an Experimental Epilepsy Model

Crossref DOI link: https://doi.org/10.1007/s12035-025-05398-z

Published Online: 2025-11-29

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Majid, Haya

Dahalia, Mansi

Ansari, Mohd. Danish

Jain, Seema

Samim, Mohammed

Nidhi, https://orcid.org/0000-0002-2509-3026
License Information

Text and Data Mining valid from 2025-11-29

Version of Record valid from 2025-11-29
More Information

Article History

Received: 1 July 2025

Accepted: 12 September 2025

First Online: 29 November 2025

Declarations

:

: All authors declare that they have no conflict of interest.

: The animals utilized in this study were sourced from the Central Animal House at Jamia Hamdard, situated in Delhi, India. The research adhered to ethical guidelines and received approval from the Institutional Animal Ethics Committee (IAEC) under registration number CAHF: 2073. The study was conducted in strict accordance with the guidelines established by the Committee for Control and Supervision of Experiments on Animals (CCSEA), registered as 173/GO/ReBi/S/2000/CPCSEA.

: This study does not contain any studies with human participants performed by any of the authors.

: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below